This cardiovascular neutrality is particularly valuable in patients with T2DM who are at high cardiovascular risk but cannot tolerate other therapies with more profound cardiovascular effects, such as SGLT2 inhibitors or GLP-1 receptor agonists [26]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.